To inhibit STAT3 activity and to perform a preclinical proof-of-concept that STAT3 is an effective molecular target for AML cells expressing mutated KIT, we used the Stattic inhibitor directly injected into the tumor as previously described in vivo26,27. The gene discussed is KIT; the disease is acute myeloid leukemia.